% | $
Quotes you view appear here for quick access.

Enzon Pharmaceuticals Inc. Message Board

  • brainless_2004 brainless_2004 Dec 20, 2012 7:09 PM Flag

    I wonder why?

    Why would they stop R&D development, even though they have enough cash to keep on and are almost break even, if not positive? I does not make sense. This is usually done by companies that have burn their cash and are cash strapped, but they have $278M available, and $162M without debt.
    The only plausible answer is that they have a preliminary Sales Agreement that includes a multiplicative % of the cash available at the time of the sale. If this is so, maybe Merck is a suitable option, given that they would not need the R&D team.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.370.00(0.00%)Sep 26 3:58 PMEDT